Promising combo aims to extend life in aggressive lung cancer

NCT ID NCT05068232

First seen Mar 17, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study tests whether adding focused radiation to a standard drug combination (durvalumab plus chemotherapy) can help people with extensive-stage small cell lung cancer live longer without the cancer getting worse. About 49 adults who have not yet been treated for this advanced lung cancer will receive the drugs plus radiation to specific tumor sites. The goal is to see if this approach improves progression-free survival compared to drugs alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Chicago Medicine

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Wisconsin Carbone Cancer Center

    ACTIVE_NOT_RECRUITING

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.